Biofrontera

BFRIPhase 3

Woburn, United StatesFounded 2015biofrontera-us.com

Biofrontera Inc. is a publicly traded, commercial-stage biopharma company dedicated to becoming a leading U.S. specialty dermatology firm. Founded in 2015 to commercialize the FDA-approved PDT drug Ameluz®, the company has since expanded its portfolio with the antibiotic Xepi® and is advancing a pipeline of PDT candidates for conditions like basal cell carcinoma and acne. With a leadership team combining deep dermatology expertise and commercial experience, Biofrontera aims to establish PDT as a standard of care while leveraging its nanoemulsion platform for future growth.

Market Cap

$10.1M

Founded

2015

Focus

Small Molecules

BFRI · Stock Price

USD 0.8758.73 (-98.54%)

Historical price data

AI Company Overview

Technology Platform

Proprietary nanoemulsion technology designed to improve drug stability and enhance skin penetration for topical formulations, particularly used in its photodynamic therapy (PDT) platform.

Pipeline Snapshot

8 drugs in pipeline, 4 in Phase 3

Drug	Indication	Stage
Ameluz 10% Topical Gel	Actinic Keratoses	Approved
BF-200 ALA + MAL Cream + Vehicle	Actinic Keratosis	Phase 3
BF-200 ALA + methyl-aminolevulinate	Basal Cell Carcinoma (BCC)	Phase 3
Vehicle + BF-200 ALA	Actinic Keratosis	Phase 3
BF-200 ALA gel + Placebo to BF-200 ALA gel	Actinic Keratosis	Phase 3

Opportunities

Significant growth opportunities exist in expanding the label of Ameluz® into large new indications like superficial basal cell carcinoma and acne, which are much larger markets than actinic keratosis.

Further optimization of PDT protocols to reduce pain and treatment time could drive higher adoption among dermatologists and patients.

Leveraging the nanoemulsion platform for new active ingredients represents a long-term platform opportunity.

Risk Factors

Key risks include commercial execution challenges against larger competitors, financial constraints given its micro-cap status, and clinical trial failure risk for its pipeline candidates.

The company is also highly dependent on the continued success and market acceptance of its flagship product, Ameluz®.

Competitive Landscape

Biofrontera competes in the actinic keratosis space with other PDT drugs, topical therapies (5-FU, imiquimod, tirbanibulin), and cryosurgery. For impetigo, it competes with topical antibiotics like mupirocin. Its differentiation is based on specialized PDT expertise, its nanoemulsion technology for enhanced drug delivery, and a focused dermatology commercial approach.